Literature DB >> 28812534

Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances.

Semir Vranic1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28812534      PMCID: PMC5581978          DOI: 10.17305/bjbms.2017.2366

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


× No keyword cloud information.
  18 in total

1.  Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.

Authors:  Zoran Gatalica; Carrie Snyder; Todd Maney; Anatole Ghazalpour; Daniel A Holterman; Nianqing Xiao; Peggy Overberg; Inga Rose; Gargi D Basu; Semir Vranic; Henry T Lynch; Daniel D Von Hoff; Omid Hamid
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-12       Impact factor: 4.254

Review 2.  PD-1/PD-L1 inhibitors.

Authors:  Joel Sunshine; Janis M Taube
Journal:  Curr Opin Pharmacol       Date:  2015-06-02       Impact factor: 5.547

Review 3.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Authors:  Valerie Lee; Adrian Murphy; Dung T Le; Luis A Diaz
Journal:  Oncologist       Date:  2016-07-13

4.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

5.  Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Authors:  Valsamo Anagnostou; Kellie N Smith; Patrick M Forde; Noushin Niknafs; Rohit Bhattacharya; James White; Theresa Zhang; Vilmos Adleff; Jillian Phallen; Neha Wali; Carolyn Hruban; Violeta B Guthrie; Kristen Rodgers; Jarushka Naidoo; Hyunseok Kang; William Sharfman; Christos Georgiades; Franco Verde; Peter Illei; Qing Kay Li; Edward Gabrielson; Malcolm V Brock; Cynthia A Zahnow; Stephen B Baylin; Robert B Scharpf; Julie R Brahmer; Rachel Karchin; Drew M Pardoll; Victor E Velculescu
Journal:  Cancer Discov       Date:  2016-12-28       Impact factor: 39.397

6.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.

Authors:  Nicolas J Llosa; Michael Cruise; Ada Tam; Elizabeth C Wicks; Elizabeth M Hechenbleikner; Janis M Taube; Richard L Blosser; Hongni Fan; Hao Wang; Brandon S Luber; Ming Zhang; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Cynthia L Sears; Robert A Anders; Drew M Pardoll; Franck Housseau
Journal:  Cancer Discov       Date:  2014-10-30       Impact factor: 39.397

7.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

8.  Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.

Authors:  Elena Czink; Matthias Kloor; Benjamin Goeppert; Stefan Fröhling; Sebastian Uhrig; Tim F Weber; Jörn Meinel; Christian Sutter; Karl Heinz Weiss; Peter Schirmacher; Magnus von Knebel Doeberitz; Dirk Jäger; Christoph Springfeld
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-09-01

9.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Authors:  Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton
Journal:  Genome Med       Date:  2017-04-19       Impact factor: 11.117

10.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

Authors:  Nicholas McGranahan; Andrew J S Furness; Rachel Rosenthal; Sofie Ramskov; Rikke Lyngaa; Sunil Kumar Saini; Mariam Jamal-Hanjani; Gareth A Wilson; Nicolai J Birkbak; Crispin T Hiley; Thomas B K Watkins; Seema Shafi; Nirupa Murugaesu; Richard Mitter; Ayse U Akarca; Joseph Linares; Teresa Marafioti; Jake Y Henry; Eliezer M Van Allen; Diana Miao; Bastian Schilling; Dirk Schadendorf; Levi A Garraway; Vladimir Makarov; Naiyer A Rizvi; Alexandra Snyder; Matthew D Hellmann; Taha Merghoub; Jedd D Wolchok; Sachet A Shukla; Catherine J Wu; Karl S Peggs; Timothy A Chan; Sine R Hadrup; Sergio A Quezada; Charles Swanton
Journal:  Science       Date:  2016-03-03       Impact factor: 47.728

View more
  6 in total

1.  Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

Authors:  Triparna Sen; B Leticia Rodriguez; Limo Chen; Carminia M Della Corte; Naoto Morikawa; Junya Fujimoto; Sandra Cristea; Thuyen Nguyen; Lixia Diao; Lerong Li; Youhong Fan; Yongbin Yang; Jing Wang; Bonnie S Glisson; Ignacio I Wistuba; Julien Sage; John V Heymach; Don L Gibbons; Lauren A Byers
Journal:  Cancer Discov       Date:  2019-02-18       Impact factor: 39.397

Review 2.  Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle.

Authors:  Angelika M Starzer; Matthias Preusser; Anna S Berghoff
Journal:  Ther Adv Med Oncol       Date:  2022-04-30       Impact factor: 5.485

3.  Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East.

Authors:  Rasha T Kakati; Walid Faraj; Taha Qaraqe; Frederic El Chaer; Hero Hussain; Ali Shamseddine; Mohamad Jawad Khalife
Journal:  J Surg Case Rep       Date:  2022-08-31

Review 4.  Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies.

Authors:  Alberto Puccini; Francesca Battaglin; Maria Laura Iaia; Heinz-Josef Lenz; Mohamed E Salem
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

Review 5.  The intracellular signalosome of PD-L1 in cancer cells.

Authors:  David Escors; María Gato-Cañas; Miren Zuazo; Hugo Arasanz; María Jesus García-Granda; Ruth Vera; Grazyna Kochan
Journal:  Signal Transduct Target Ther       Date:  2018-09-28

Review 6.  Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions.

Authors:  Francesca Battaglin; Madiha Naseem; Alberto Puccini; Heinz-Josef Lenz
Journal:  Cancer Cell Int       Date:  2018-07-11       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.